Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars C Huber

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|February 12, 2016
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPDCaroline Leuenberger, Claudio Schuoler, Hannah Bye, et al.
Arthritis and Rheumatism|March 30, 2007
Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patientsLars C Huber, Matthias Brock, Hossein Hemmatazad, et al.
Nature Communications|January 26, 2022
Immunoglobulin signature predicts risk of post-acute COVID-19 syndromeCarlo Cervia, Yves Zurbuchen, Patrick Taeschler, et al.
Trials|January 5, 2021
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)Pascal Urwyler, Panteleimon Charitos, Stephan Moser, et al.
Allergy|April 22, 2021
Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19Sarah Adamo, Stéphane Chevrier, Carlo Cervia, et al.
Allergy|April 1, 2022
Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signaturesPatrick Taeschler, Carlo Cervia, Yves Zurbuchen, et al.
Cell Reports. Medicine|February 1, 2021
A distinct innate immune signature marks progression from mild to severe COVID-19Stéphane Chevrier, Yves Zurbuchen, Carlo Cervia, et al.
Frontiers in Immunology|November 15, 2023
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trialPascal Urwyler, Marina Leimbacher, Panteleimon Charitos, et al.
Plos One|September 28, 2023
Association of part-time clinical work with well-being and mental health in General Internal Medicine: A survey among Swiss hospitalistsLisa Bretagne, Stefanie Mosimann, Christine Roten, et al.
Respiration; International Review of Thoracic Diseases|February 10, 2015
Long-term data from the Swiss pulmonary hypertension registrySéverine Mueller-Mottet, Hans Stricker, Guido Domenighetti, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Journal of Molecular Medicine (Berlin, Germany)|February 12, 2016
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPDCaroline Leuenberger, Claudio Schuoler, Hannah Bye, et al.
Arthritis and Rheumatism|March 30, 2007
Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patientsLars C Huber, Matthias Brock, Hossein Hemmatazad, et al.
Nature Communications|January 26, 2022
Immunoglobulin signature predicts risk of post-acute COVID-19 syndromeCarlo Cervia, Yves Zurbuchen, Patrick Taeschler, et al.
Trials|January 5, 2021
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)Pascal Urwyler, Panteleimon Charitos, Stephan Moser, et al.
Allergy|April 22, 2021
Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19Sarah Adamo, Stéphane Chevrier, Carlo Cervia, et al.
Allergy|April 1, 2022
Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signaturesPatrick Taeschler, Carlo Cervia, Yves Zurbuchen, et al.
Cell Reports. Medicine|February 1, 2021
A distinct innate immune signature marks progression from mild to severe COVID-19Stéphane Chevrier, Yves Zurbuchen, Carlo Cervia, et al.
Frontiers in Immunology|November 15, 2023
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trialPascal Urwyler, Marina Leimbacher, Panteleimon Charitos, et al.
Plos One|September 28, 2023
Association of part-time clinical work with well-being and mental health in General Internal Medicine: A survey among Swiss hospitalistsLisa Bretagne, Stefanie Mosimann, Christine Roten, et al.
Respiration; International Review of Thoracic Diseases|February 10, 2015
Long-term data from the Swiss pulmonary hypertension registrySéverine Mueller-Mottet, Hans Stricker, Guido Domenighetti, et al.
Pageof 13